XML 16 R39.htm IDEA: XBRL DOCUMENT v3.3.0.814
Pro Forma Information – Vitro Acquisition (Tables)
9 Months Ended
Sep. 30, 2015
Pro Forma Information – Vitro Acquisition  
Schedule of pro-forma informations

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended September 30, 2015

 

 

    

As

    

Acquisition

    

Financing

    

Pro Forma

 

 

 

Reported

 

Adjustments

 

Adjustments

 

As Adjusted

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

1,566

$

143

$

 —

$

1,709

 

 

 

 

 

 

 

 

 

 

 

Earnings from continuing operations attributable to the Company

 

18

 

18

 

(11)

 

25

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share from continuing operations

 

0.11

 

 

 

 

 

0.15

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine months ended September 30, 2015

 

 

    

As

    

Acquisition

    

Financing

    

Pro Forma

 

 

 

Reported

 

Adjustments

 

Adjustments

 

As Adjusted

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

4,530

$

574

$

 —

$

5,104

 

 

 

 

 

 

 

 

 

 

 

Earnings from continuing operations attributable to the Company

 

131

 

79

 

(46)

 

164

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share from continuing operations

 

0.81

 

 

 

 

 

1.01

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended September 30, 2014

 

 

    

As

    

Acquisition

    

Financing

    

Pro Forma

 

 

 

Reported

 

Adjustments

 

Adjustments

 

As Adjusted

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

1,745

$

224

$

 —

$

1,969

 

 

 

 

 

 

 

 

 

 

 

Earnings from continuing operations attributable to the Company

 

61

 

25

 

(18)

 

68

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share from continuing operations

 

0.37

 

 

 

 

 

0.41

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine months ended September 30, 2014

 

 

    

As

    

Acquisition

    

Financing

    

Pro Forma

 

 

 

Reported

 

Adjustments

 

Adjustments

 

As Adjusted

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

5,181

$

651

$

 —

$

5,832

 

 

 

 

 

 

 

 

 

 

 

Earnings from continuing operations attributable to the Company

 

297

 

64

 

(53)

 

308

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share from continuing operations

 

1.79

 

 

 

 

 

1.85